Effects of atorvastatin on systemic inflammatory response after coronary bypass surgery

Critical Care Medicine

Volumn 34, Issue 3, 2006, Pages 660-667

  Chello, Massimo ^a   Patti, Giuseppe ^a   Candura, Dario ^a   Mastrobuoni, Stefano ^a   Di Sciascio, Germano ^a   Agrò, Felice ^a   Carassiti, Massimiliano ^a   Covino, Elvio ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Atorvastatin; Cardiopulmonary bypass; Cytokines; Neutrophils; Systemic inflammatory response syndrome

Indexed keywords

ATORVASTATIN; CD11B ANTIGEN; INTERLEUKIN 6; INTERLEUKIN 8; PLACEBO;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BLEEDING; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; CYTOKINE RELEASE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HOSPITALIZATION; HUMAN; INOTROPISM; INTENSIVE CARE UNIT; INTUBATION; LENGTH OF STAY; MALE; MORBIDITY; NEUTROPHIL; OPERATION DURATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; UNIVERSITY HOSPITAL;

AGED; ANALYSIS OF VARIANCE; CORONARY ARTERY BYPASS; CYTOKINES; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; NEUTROPHIL ACTIVATION; POSTOPERATIVE COMPLICATIONS; PYRROLES; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 33644595198     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000201407.89977.EA     Document Type: Article

References (34)

1. Boyle EM, Pohlman TH, Johnson MC, et al: Endothelial cell injury in cardiovascular surgery: The systemic inflammatory response. Ann Thorac Surg 1997; 62:1549-1557
2. Paparella D, Yau TM, Young E: Cardiopulmonary bypass induced inflammation: Pathophysiology and treatment. An update. Eur J Cardiothorac Surg 2002; 21:232-244
3. Kubala L, Ciz M, Vondracek J, et al: Perioperative and postoperative course of cytokines and the metabolic activity of neutrophils in human cardiac operations and heart transplantation. J Thorac Cardiovasc Surg 2002; 124:1122-1129
4. Hill GE, Whitten CW, Landers DF: The influence of cardiopulmonary bypass of cytokine and cell to cell communication. J Cardiothorac Vasc Anesthesia 1997; 11:367-375
5. Hennein HA, Ebba H, Rodriguez JL, et al: Relationship of the proinflammatory cytokines to myocardial ischemia and dysfunction after uncomplicated coronary revascularization. J Thorac Cardiovasc Surg 1994; 108:626-635
6. Casey LC: Role of cytokines in the pathogenesis of cardiopulmonary induced multisystem organ failure. Ann Thorac Surg 1993; 56:S92-S96
7. Kawahito K, Kobayashi E, Ohmori M, et al: Enhanced responsiveness of circulatory neutrophils after cardiopulmonary bypass: Increased aggregability and superoxide producing capacity. Artif Organs 2000; 24:37-42
8. Partrick DA, Moore EE, Fullerton DA, et al: Cardiopulmonary bypass renders patients at risk for multiple organ failure via early neutrophil priming and late neutrophils disability. J Surg Res 1999; 86:42-49
9. Menaschè P: The systemic factor: The comparative roles of cardiopulmonary bypass and off pump surgery in the genesis of patient injury during and following cardiac surgery. Ann Thorac Surg 2001; 72:S2260-S2266
10. Sacks FM, Pfeffer MA, Moye LA, et al: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335:1001-1009
11. Lee CH, de Feyter P, Serruys PW, et al: Beneficial effects of fluvastatin following percutaneous coronary intervention in patients with unstable and stable angina: Results from the Lescol intervention prevention study (LIPS). Heart 2004; 90:1156-1161
12. Datani MI, Elnicki M, Jain AC, et al: Effect of preoperative statin therapy and cardiac outcome after coronary artery bypass grafting. Am J Cardiol 2000; 86:1128-1130
13. Pan W, Pintar T, Anton J, et al: Statins are associated with a reduced incidence of perioperative mortality after coronary artery bypass graft surgery. Circulation 2004; 110(11 suppl 1):II45-II49
14. Lefer AM, Scalia R, Lefer DJ: Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: New concept for cardiovascular disease. Cardiovasc Res 2001; 49:281-287
15. Miller SJ: Emerging mechanisms for secondary cardioprotective effects of statins. Cardiovasc Res 2001; 52:5-7
16. Lazar HL, Bao Y, Zhang Y, et al: Pretreatment with statins enhances myocardial protection during coronary revascularization, J Thorac Cardiovasc Surg, 2003; 125:1037-1042
17. Tobin MJ: Advances in mechanical ventilation. N Engl J Med 2001; 344:1986-1996
18. American College of Chest Physicians/ Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and organ failure, and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20:864-874
19. Talmor M, Hydo L, Barie PS: Relationship of systemic inflammatory response syndrome to organ dysfunction, length of stay, and mortality in critical surgical illness. Arch Surg 1999; 134:81-87
20. Malone DL, Kuhls D, Napolitano LM, et al: Back to basics: validation of the admission systemic inflammatory response syndrome score in predicting outcome in trauma. J Trauma 2001; 51:458-463
21. Ma X, Weyrich AS, Lefer DJ, et al: Diminished basal nitric oxide release after myocardial ischemia and reperfusion promotes neutrophil adherence to coronary endothelium. Circ Res 1993; 72:403-412
22. Chello M, Mastroroberto P, Perticone F, et al: Nitric oxide modulation of neutrophil-endothelium interaction: Difference between arterial and venous coronary bypass grafts. J Am Coll Cardiol 1998; 31:823-826
23. Azar RR, Badaoui G, Sarkis A, et al: Effects of tirofiban and statins on high-sensitivity C-reactive protein, interleukin-6, and soluble CD40 ligand following percutaneous coronary interventions in patients with stable coronary artery disease. Am J Cardiol 2005; 95:236-240
24. Jialal I, Stein D, Balis D, et al: Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001; 103:1933-1935
25. Weber C, Erl W, Weber KSC, et al: HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol 1997; 30:1212-1217
26. Chello M, Mastroroberto P, Patti G, et al: Simvastatin attenuates leucocyte-endothelial interactions after coronary revascularisation with cardiopulmonary bypass. Heart 2003; 89:538-543
27. Lefer AM, Campbell B, Shin YK, et al: Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. Circulation 1999; 100:178-184
28. Rangel-Frausto MS, Pittet D, Costigan M, et al: The natural history of the systemic inflammatory response syndrome (SIRS). JAMA 1995; 273:117-123
29. Rezaie-Majd A, Maca T, Bucek RA, et al: Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 2002; 22:1194-1199
30. Kinlay S, Schwartz GG, Olsson AG, et al: High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation 2003; 108:1560-1566
31. Laufs U, La Fata V, Liao JK: Inhibition of 3-hydroxyy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down regulation of endothelial nitric oxide synthase. J Biol Chem 1997; 272:31725-31729
32. Wassmann S, Laufs U, Baumerr AT, et al: HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 2001; 37:1450-1457
33. Endres M, Laufs U, Huamg Z, et al: Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci U S A 1998; 95:8880-8885
34. Vincent JL: Dear SIRS, I'm sorry to say that I don't like you. Crit Care Med 1997; 25:372-374